Latest Regulatory Approval News

Neurizon Therapeutics has secured FDA clearance to resume clinical trials for its lead ALS drug NUZ-001, alongside a $5.2 million capital raise and a key licensing deal with Elanco Animal Health. These developments position the company for a critical growth phase in neurodegenerative disease therapeutics.

Strategic Energy Resources has advanced its copper-gold exploration in Queensland through government-backed drilling, a $3 million joint venture program, and a key acquisition from Anglo American, supported by a $2 million capital raise.

Cue Energy Resources reported steady production with notable gains at Mahato and Maari fields, alongside a new gas supply deal and a $3.5 million dividend payment.

CuFe Ltd has announced a dramatic 400% increase in contained copper at its Gecko project, alongside an upgraded Orlando resource and a $5.4 million capital raise to advance its Tennant Creek development plans.

Archer Materials has successfully demonstrated that its blood potassium Biochip can be fabricated on a silicon platform, matching clinical accuracy standards and accelerating its path to commercialisation.

Alligator Energy has commenced construction of its pivotal Samphire Field Recovery Trial, marking a significant shift from exploration to development. The company also bolstered its leadership team to support this growth phase and reported promising exploration results at its Big Lake Uranium Project.

INOVIQ Limited has raised $9.5 million to advance its pioneering ovarian cancer screening test and CAR-exosome therapeutic programs, backed by strong preclinical data and strategic partnerships.

Orthocell has appointed MontsMed as the exclusive distributor for its nerve repair product Remplir™ in Hong Kong, marking a significant step in its Asian commercialisation strategy. This move opens access to the vast Guangdong-Hong Kong-Macao Greater Bay Area, complementing existing operations in Singapore and planned expansion in Thailand.

Dimerix Limited reports solid progress in its Phase 3 trial for DMX-200 targeting rare kidney disease FSGS, backed by orphan drug status in Japan and a robust cash position. The company prepares to engage the FDA on new data supporting regulatory approval.

Capricorn Metals delivered record gold production and cash flow in Q1 FY26, progressing its Karlawinda Expansion Project and securing a key acquisition to bolster its resource base.

Immutep Limited reports strong progress in its Phase III lung cancer trial with over 170 patients enrolled, alongside positive FDA feedback and a robust cash position supporting ongoing development.

Ragusa Minerals has agreed to acquire a controlling stake in Pegasus Tel Inc., gaining access to the Purple Pansy manganese-gold project in Arizona, a critical asset aligned with US strategic mineral priorities.